This is a Phase 2 clinical research study of investigational drug XT-150 in participants experiencing moderate to severe pain due to osteoarthritis of the knee.
XT-150 is a plasmid DNA that will be injected into the intra-articular space of the affected knee, and has been shown to reduce inflammation through cytokine IL-10. The possible benefits of this clinical study include increased mobility following a single dose, reduction in requirement for pain medications/therapies, and reduction in pain symptoms.
If you are interested in this study, you will be sent an online pre-screening questionnaire to further determine your eligibility. If you meet all the study criteria and consent to take part in the study, you will be coming to our clinical site for monthly visits over the course of 1 year.
Criteria:
- Be between the ages of 45 and 85
- Have a clinical diagnosis of Grade 2 or 3 knee osteoarthritis
- No scheduled partial or complete knee replacement within 6 months
- No history of rheumatoid arthritis or other inflammatory disease
- No current treatment with systemic immunosuppressants, steroids, antibiotics, or antivirals